Medical technology giant Becton Dickinson & Co. announced Thursday it has reached a settlement of $22 million to end four class action lawsuits against the firm accusing the company of attempting to monopolize the hypodermic needle market. Specifically, members of the class action claimed BD of squeezing competitors out of the market by offering steep discounts on bundled hospital equipment products so long as hospitals agreed to buy the majority of their needles from BD. Further, BD was accused of giving company stock to group purchasing organizations, which determine prices set for hospitals. Court documents allege that such agreements were anticompetitive, violated antitrust law, raised prices and reduced innovation. The company announced the settlement along with its third-quarter earnings report. BD says the settlement cut share prices by 7 cents.
Featured News
France Competition Watchdog Dismisses Qwant Complaint Against Microsoft
Dec 21, 2025 by
CPI
US Regulators Clear Nvidia–Intel Technology Tie-Up
Dec 21, 2025 by
CPI
European Union Reaches Landmark Agreement on Digital Euro Framework
Dec 21, 2025 by
CPI
Trump Announces New Drug Pricing Deals With Major Pharmaceutical Companies
Dec 21, 2025 by
CPI
Coinbase Sues Three States Over Prediction Market Regulations
Dec 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi